SAN DIEGO–(BUSINESS WIRE)–Element Biosciences, Inc. today announced that the Regional Court of Munich I (Landgericht München I) has ruled that Illumina, Inc. and its German subsidiary, Illumina GmbH, infringe patent rights controlled by Element covering an imaging method used in DNA sequencing. The court found Illumina liable for both direct infringement, through Illumina’s own use of the patented method in Germany, and indirect infringement, through the offer and supply of sequencing systems
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
